Targeting aberrant signaling pathways

Jacob Mandel; Santosh Kesari

doi:10.1007/978-3-319-49864-5_9

Targeting aberrant signaling pathways

Jacob Mandel
, Santosh Kesari

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Scopus citations

Abstract

Malignant gliomas are the most common primary brain tumors in adults. Prognosis remains dismal despite aggressive treatment with surgical resection, radiation, and chemotherapy. The use of advanced sequencing technologies and large-scale gene expression studies has provided an in-depth description of the distinct molecular and genetic alterations in glioblastoma inspiring interest in the development of targeted therapies. Unfortunately, despite trials with several agents and different pathways, targeted therapies have currently failed to improve the overall survival of glioblastoma patients. New therapies examining novel targets and innovative drug combinations are presently under investigation that will hopefully prove more beneficial.

Original language	English
Title of host publication	Malignant Brain Tumors
Subtitle of host publication	State-of-the-Art Treatment
Publisher	Springer International Publishing
Pages	133-150
Number of pages	18
ISBN (Electronic)	9783319498645
ISBN (Print)	9783319498638
DOIs	https://doi.org/10.1007/978-3-319-49864-5_9
State	Published - Jan 1 2016

Keywords

Malignant glioma
Receptor tyrosine kinase pathway
Retinoblastoma pathway
Targeted therapy
The cancer genome atlas
p53 pathway

Access to Document

10.1007/978-3-319-49864-5_9

Cite this

@inbook{cc03a989d53b44b688fdbd37cdbe6b25,

title = "Targeting aberrant signaling pathways",

abstract = "Malignant gliomas are the most common primary brain tumors in adults. Prognosis remains dismal despite aggressive treatment with surgical resection, radiation, and chemotherapy. The use of advanced sequencing technologies and large-scale gene expression studies has provided an in-depth description of the distinct molecular and genetic alterations in glioblastoma inspiring interest in the development of targeted therapies. Unfortunately, despite trials with several agents and different pathways, targeted therapies have currently failed to improve the overall survival of glioblastoma patients. New therapies examining novel targets and innovative drug combinations are presently under investigation that will hopefully prove more beneficial.",

keywords = "Malignant glioma, Receptor tyrosine kinase pathway, Retinoblastoma pathway, Targeted therapy, The cancer genome atlas, p53 pathway",

author = "Jacob Mandel and Santosh Kesari",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing AG 2017.",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-49864-5\_9",

language = "English",

isbn = "9783319498638",

pages = "133--150",

booktitle = "Malignant Brain Tumors",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Targeting aberrant signaling pathways

AU - Mandel, Jacob

AU - Kesari, Santosh

N1 - Publisher Copyright: © Springer International Publishing AG 2017.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Malignant gliomas are the most common primary brain tumors in adults. Prognosis remains dismal despite aggressive treatment with surgical resection, radiation, and chemotherapy. The use of advanced sequencing technologies and large-scale gene expression studies has provided an in-depth description of the distinct molecular and genetic alterations in glioblastoma inspiring interest in the development of targeted therapies. Unfortunately, despite trials with several agents and different pathways, targeted therapies have currently failed to improve the overall survival of glioblastoma patients. New therapies examining novel targets and innovative drug combinations are presently under investigation that will hopefully prove more beneficial.

AB - Malignant gliomas are the most common primary brain tumors in adults. Prognosis remains dismal despite aggressive treatment with surgical resection, radiation, and chemotherapy. The use of advanced sequencing technologies and large-scale gene expression studies has provided an in-depth description of the distinct molecular and genetic alterations in glioblastoma inspiring interest in the development of targeted therapies. Unfortunately, despite trials with several agents and different pathways, targeted therapies have currently failed to improve the overall survival of glioblastoma patients. New therapies examining novel targets and innovative drug combinations are presently under investigation that will hopefully prove more beneficial.

KW - Malignant glioma

KW - Receptor tyrosine kinase pathway

KW - Retinoblastoma pathway

KW - Targeted therapy

KW - The cancer genome atlas

KW - p53 pathway

UR - https://www.scopus.com/pages/publications/85042829862

U2 - 10.1007/978-3-319-49864-5_9

DO - 10.1007/978-3-319-49864-5_9

M3 - Chapter

AN - SCOPUS:85042829862

SN - 9783319498638

SP - 133

EP - 150

BT - Malignant Brain Tumors

PB - Springer International Publishing

ER -

Targeting aberrant signaling pathways

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this